Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (Rinvoq®▼) for active ankylosing spondylitis

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 26 - Oct - 2022
Body System:
Red
UPADACITINIB prolonged-release tablets (Rinvoq®▼) for active ankylosing spondylitis

The Pan Mersey Area Prescribing Committee recommends the prescribing of UPADACITINIB prolonged-release tablets (Rinvoq®▼), by specialists only, for treating active ankylosing spondylitis in accordance with NICE TA829.

NHS Cheshire and Merseyside APPROVED